A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to address the longtime challenge of bringing their treatments to patients by ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...